Giuseppe Bellelli: Reevaluating Anticoagulation Net Benefit in Frail Older Adults
Giuseppe Bellelli, Elected President at SIGG – Italian Society of Gerontology and Geriatrics, shared a post on LinkedIn:
“A recent study published in JAMA Network Open highlights an important clinical message:
The presence of atrial fibrillation and a high CHA₂DS₂-VASc score alone may not be sufficient to establish the net clinical benefit of anticoagulation in older adults with severe functional disability.
Anticoagulation decisions should go beyond conventional risk scores, incorporating frailty, life expectancy, bleeding risk, goals of care, and, importantly, patient preferences.
The key question is not simply whether a patient is at high risk of stroke, but whether anticoagulation offers a meaningful net benefit in the context of their overall health and care priorities.”
Stay updated with Hemostasis Today.
-
Oct 11, 2026, 16:17Johnathan Whetstine: How Does MYC Go From 2 Copies to an Amplified Oncogene?
-
Oct 11, 2026, 16:03Parth Parmar: Practical Guidelines for Managing Venous Thromboembolism
-
Oct 11, 2026, 15:31Muhammad Alvi: CASPR Study Explores Treatment Response Across ESUS Phenotypes
-
Oct 11, 2026, 15:15Thalassaemia International Federation Joins ASCAT 2026 to Advance Sickle Cell and Thalassaemia Care
-
Oct 11, 2026, 15:14Challenges and Perspectives on Gene Therapy in Hemophilia A – Seminars in Thrombosis and Hemostasis
-
Oct 11, 2026, 15:07Neysa Rahardjo: Platelet Estimation Pitfalls and Discrepancy Resolution
-
Oct 11, 2026, 15:05Lance Trewhella: Reflections from the ASCLS Region V Fall Symposium
-
Oct 11, 2026, 15:04The Anti-Inflammatory Rationale for GLP-1 Agonists in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Oct 11, 2026, 15:00Donja W.: Blood Shortages Aren’t Just Statistics